2-(9H-fluoren-9-yl)-1H-benzimidazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-(9H-fluoren-9-yl)-1H-benzimidazole
• 化学式: C₂₀H₁₄N₂
• 分子量: 282.345
• InChiKey: CTXLFZJKNMIZHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  9-芴甲酸 在 溶剂黄146 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 2-(9H-fluoren-9-yl)-1H-benzimidazole
  参考文献：
  名称：

  将位阻二酰基化的1,2-苯二胺转化为2-取代的苯并咪唑。

  摘要：

  设计了一系列大体积的2-取代的苯并咪唑，以便为几个生物学靶标找到新的潜在客户。由它们的单酰化的对应物通过环脱水形成显示出强烈地依赖于酰基的性质。在二环己基甲基的情况下，仅在对称二酰基化前体的对甲苯磺酸/甲苯混合物中观察到环化。从混合二酰化衍生物开始分析机理。

  DOI：

  10.1248/cpb.53.492

文献信息

• HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
  申请人：Bertin Luc

  公开号：US20120010241A1

  公开（公告）日：2012-01-12

  The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R′1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A′), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.

  本发明涉及具有公式(I)的新产品，其中：R4代表H，CH3，CH2CH3，CF3，F，Cl，Br，I；Het代表一个杂环，可选地由一个或多个R1或R'1自由基取代，这些自由基选自H，卤素，CF3，硝基，腈基，烷基，羟基，巯基，氨基，烷基氨基，二烷基氨基，烷氧基，苯基烷氧基，烷基硫醚，游离或与烷基自由基酯化的羧基，羧酰胺，CO—NH(烷基)，CON(烷基)2，NH—CO-烷基，磺酰胺，NH—SO2-烷基，S(O)2-NH烷基，S(O2)-N(烷基)2，所有烷基，烷氧基和烷基硫醚自由基都是可选取代的；R选自包括(A′)，(B)，(C)，(D)和(F)的组，其中W1，W2，W3独立代表CH或N，X代表O，S，NR2，C(O)，S(O)或S(O)2；V代表H，Hal，—O—R2或—NH—R2，R2代表H，烷基，环烷基或杂环烷基，可选取代；所述产品为所有异构体形式，以及盐，用于作为药物使用。
• NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
  申请人：RUXER Jean-Marie

  公开号：US20110166169A1

  公开（公告）日：2011-07-07

  The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R′1; R is selected from the group comprising Formula (A′), (B), (C), (D), or (E), with R1 and/or R′1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.

  该发明涉及式（I）中的新物质：其中Het是一种杂环，可选择地由一个或多个基团R1或R′1取代；R从包括式（A′）、（B）、（C）、（D）或（E）的基团中选择，其中R1和/或R′1从H、卤素、CF3、硝基、氰基、烷基、羟基、巯基、氨基、烷基氨基、二烷基氨基、烷氧基、苯基氧基、烷硫基或自由或被烷基、羧酰胺、CO—NH（烷基）、CON（烷基）2、NH—CO-烷基、磺酰胺、NH—S02-烷基、S(0)2-NH烷基或S(02)-N(烷基)2基团中选择；所有这些基团可选择地被取代；W1、W2和W3独立地是CH或N；X是0、S、NR2、C(O)、S(O)或S(0)2；Z是可选择地取代的H、卤素、-0-R2或—NH—R2，其中R2是H、烷基、环烷基或杂环烷基；这些物质都是同分异构体和其盐，用作药物。
• Conversion of Sterically Hindered Diacylated 1,2-Phenylenediamines into 2-Substituted Benzimidazoles
  作者：Julie Charton、Sophie Girault-Mizzi、Christian Sergheraert

  DOI：10.1248/cpb.53.492

  日期：——

  for several biological targets. Formation by cyclodehydration from their monoacylated counterparts was shown to be strongly dependent upon the nature of the acyl group. In the case of a dicyclohexylmethyl group, cyclization was only observed in a p-toluenesulfonic acid/toluene mixture from the symmetrical diacylated precursor. Analysis of the mechanism was begun starting from mixed diacylated derivatives

  设计了一系列大体积的2-取代的苯并咪唑，以便为几个生物学靶标找到新的潜在客户。由它们的单酰化的对应物通过环脱水形成显示出强烈地依赖于酰基的性质。在二环己基甲基的情况下，仅在对称二酰基化前体的对甲苯磺酸/甲苯混合物中观察到环化。从混合二酰化衍生物开始分析机理。
• NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF
  申请人：Alasia Marcel

  公开号：US20110184015A1

  公开（公告）日：2011-07-28

  Pyrroloindoles of formula (I) are provided wherein Het is an aromatic or partially unsaturated, monocyclic or bicyclic heterocycle containing between 1 and 4 heteroatoms N, O or S, optionally substituted by R1 or R′1 which are the same or different; R is X-(A-B)n-CONH2, X-(A-B)n-O—CONH2, X-(A-B)n-NH—CONH2, X—(CH2)m-heterocycloalkyl, X(CH2)m-aryl and X—(CH2)m-heteroaryl wherein X is —O—C(O), —NH—C(O), NH—CS, —NH—CO—CH2-O—; —NH—COCH2-S—CH2-CO—NH—; —NH—CO—(CH2)2-SO2-; and —NH—CO—CH2-N(CH3)-CO—; A and B are the same or different and are each independently a single bond, CH2, CH-alkyl, and CH-aralkyl; n=1,2 and m=0, 1; R1 and/or R′1 are H, halogen, CF3, nitro, cyano, alkyle, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, and carboxy, free or esterified by an alkyl, carboxamide, CONH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, and S(O2)-N(alkyl)2 group, all of said alkyl, alcoxy and alkylthio groups being optionally substituted themselves, said products being in all isomer forms and salts, as medicaments.

  提供了式（I）的吡咯吲哚，其中Het是含有1至4个杂原子N、O或S的芳香或部分不饱和的单环或双环杂环，可以由R1或R′1取代，它们可以相同也可以不同；R是X-(A-B)n-CONH2，X-(A-B)n-O—CONH2，X-(A-B)n-NH—CONH2，X—(CH2)m-杂环烷基，X(CH2)m-芳基和X—(CH2)m-杂芳基，其中X是—O—C(O)，—NH—C(O)，NH—CS，—NH—CO—CH2-O—；—NH—COCH2-S—CH2-CO—NH—；—NH—CO—(CH2)2-SO2-；和—NH—CO—CH2-N(CH3)-CO—；A和B相同或不同，分别是单键，CH2，CH-烷基和CH-芳烷基；n=1,2，m=0,1；R1和/或R′1是H，卤素，CF3，硝基，氰基，烷基，羟基，巯基，氨基，烷基氨基，二烷基氨基，烷氧基，烷基硫基和羧基，均为自由或被烷基、羧酰胺、CONH(烷基)、CON(烷基)2、NH—CO-烷基、磺酰胺、NH—SO2-烷基、S(O)2-NH烷基和S(O2)-N(烷基)2基酯化的，所述的所有烷基、烷氧基和烷基硫基基团本身也可以被取代，所述产品以所有异构体形式和盐形式作为药物。
• NOUVEAUX DERIVES DE CARBAZOLE INHIBITEURS D' HSP90, COMPOSITIONS LES CONTENANT ET UTILISATION
  申请人：Sanofi-Aventis

  公开号：EP2265598A2

  公开（公告）日：2010-12-29